{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,26]],"date-time":"2026-08-26T07:21:20Z","timestamp":1787728880854,"version":"build-2784847793"},"reference-count":35,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,7,24]],"date-time":"2025-07-24T00:00:00Z","timestamp":1753315200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2025,7,24]],"date-time":"2025-07-24T00:00:00Z","timestamp":1753315200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"DOI":"10.13039\/501100003725","name":"National Research Foundation of Korea","doi-asserted-by":"publisher","award":["RS-2022-NR069133"],"award-info":[{"award-number":["RS-2022-NR069133"]}],"id":[{"id":"10.13039\/501100003725","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Chonnam National University Hospital Biomedical Research Institute","award":["BCRI24016"],"award-info":[{"award-number":["BCRI24016"]}]},{"DOI":"10.13039\/501100003710","name":"Korea Health Industry Development Institute","doi-asserted-by":"publisher","award":["RS-2023-00302146"],"award-info":[{"award-number":["RS-2023-00302146"]}],"id":[{"id":"10.13039\/501100003710","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"DOI":"10.1038\/s41598-025-12222-0","type":"journal-article","created":{"date-parts":[[2025,7,24]],"date-time":"2025-07-24T10:14:30Z","timestamp":1753352070000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":6,"title":["Chlorogenic acid attenuates cardiac hypertrophy and fibrosis by downregulating galectin 3"],"prefix":"10.1038","volume":"15","author":[{"given":"Seong Hoon","family":"Kim","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hae Jin","family":"Kee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hongyan","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hyukjin","family":"Park","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Seung Hun","family":"Lee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Doo Sun","family":"Sim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Myung Ho","family":"Jeong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Young Joon","family":"Hong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,7,24]]},"reference":[{"key":"12222_CR1","doi-asserted-by":"publisher","first-page":"929","DOI":"10.3389\/fphar.2017.00929","volume":"8","author":"F Yang","year":"2017","unstructured":"Yang, F. et al. Chlorogenic acid inhibits liver fibrosis by blocking the miR-21-regulated TGF-beta1\/Smad7 signaling pathway in vitro and in vivo. Front. Pharmacol. 8, 929. https:\/\/doi.org\/10.3389\/fphar.2017.00929 (2017).","journal-title":"Front. Pharmacol."},{"key":"12222_CR2","doi-asserted-by":"publisher","first-page":"106505","DOI":"10.1016\/j.phrs.2022.106505","volume":"186","author":"A Gupta","year":"2022","unstructured":"Gupta, A., Atanasov, A. G., Li, Y., Kumar, N. & Bishayee, A. Chlorogenic acid for cancer prevention and therapy: Current status on efficacy and mechanisms of action. Pharmacol. Res. 186, 106505. https:\/\/doi.org\/10.1016\/j.phrs.2022.106505 (2022).","journal-title":"Pharmacol. Res."},{"issue":"1","key":"12222_CR3","doi-asserted-by":"publisher","first-page":"81","DOI":"10.1007\/s00011-013-0674-4","volume":"63","author":"SJ Hwang","year":"2014","unstructured":"Hwang, S. J., Kim, Y. W., Park, Y., Lee, H. J. & Kim, K. W. Anti-inflammatory effects of chlorogenic acid in lipopolysaccharide-stimulated RAW 2647 cells. Inflamm. Res. 63(1), 81\u201390. https:\/\/doi.org\/10.1007\/s00011-013-0674-4 (2014).","journal-title":"Inflamm. Res."},{"key":"12222_CR4","doi-asserted-by":"publisher","DOI":"10.3390\/nu8010016","author":"N Liang","year":"2015","unstructured":"Liang, N. & Kitts, D. D. Role of chlorogenic acids in controlling oxidative and inflammatory stress conditions. Nutrients https:\/\/doi.org\/10.3390\/nu8010016 (2015).","journal-title":"Nutrients"},{"key":"12222_CR5","doi-asserted-by":"publisher","DOI":"10.3390\/molecules29040760","author":"K He","year":"2024","unstructured":"He, K., Wang, X., Li, T., Li, Y. & Ma, L. Chlorogenic acid attenuates isoproterenol hydrochloride-induced cardiac hypertrophy in AC16 cells by inhibiting the Wnt\/beta-catenin signaling pathway. Molecules https:\/\/doi.org\/10.3390\/molecules29040760 (2024).","journal-title":"Molecules"},{"issue":"3","key":"12222_CR6","doi-asserted-by":"publisher","first-page":"1580","DOI":"10.1002\/ehf2.14707","volume":"11","author":"P Ping","year":"2024","unstructured":"Ping, P. et al. Chlorogenic acid attenuates cardiac hypertrophy via up-regulating Sphingosine-1-phosphate receptor1 to inhibit endoplasmic reticulum stress. ESC Heart Fail. 11(3), 1580\u20131593. https:\/\/doi.org\/10.1002\/ehf2.14707 (2024).","journal-title":"ESC Heart Fail."},{"issue":"5","key":"12222_CR7","doi-asserted-by":"publisher","first-page":"165","DOI":"10.31083\/j.rcm2305165","volume":"23","author":"A Caturano","year":"2022","unstructured":"Caturano, A. et al. Cardiac hypertrophy: From pathophysiological mechanisms to heart failure development. Rev. Cardiovasc. Med. 23(5), 165. https:\/\/doi.org\/10.31083\/j.rcm2305165 (2022).","journal-title":"Rev. Cardiovasc. Med."},{"key":"12222_CR8","doi-asserted-by":"publisher","first-page":"77","DOI":"10.1016\/j.addr.2019.05.011","volume":"146","author":"S Hinderer","year":"2019","unstructured":"Hinderer, S. & Schenke-Layland, K. Cardiac fibrosis: A short review of causes and therapeutic strategies. Adv. Drug Deliv. Rev. 146, 77\u201382. https:\/\/doi.org\/10.1016\/j.addr.2019.05.011 (2019).","journal-title":"Adv. Drug Deliv. Rev."},{"issue":"1","key":"12222_CR9","doi-asserted-by":"publisher","first-page":"72","DOI":"10.1161\/CIRCHEARTFAILURE.111.963637","volume":"5","author":"GM Felker","year":"2012","unstructured":"Felker, G. M. et al. Galectin-3 in ambulatory patients with heart failure: Results from the HF-ACTION study. Circ. Heart Fail. 5(1), 72\u201378. https:\/\/doi.org\/10.1161\/CIRCHEARTFAILURE.111.963637 (2012).","journal-title":"Circ. Heart Fail."},{"key":"12222_CR10","doi-asserted-by":"publisher","DOI":"10.3390\/ijms241713111","author":"B Zaborska","year":"2023","unstructured":"Zaborska, B. et al. The role of galectin-3 in heart failure-the diagnostic, prognostic and therapeutic potential-where do we stand?. Int. J. Mol. Sci. https:\/\/doi.org\/10.3390\/ijms241713111 (2023).","journal-title":"Int. J. Mol. Sci."},{"issue":"1","key":"12222_CR11","doi-asserted-by":"publisher","first-page":"75","DOI":"10.1016\/j.hfc.2017.08.009","volume":"14","author":"C Gehlken","year":"2018","unstructured":"Gehlken, C., Suthahar, N., Meijers, W. C. & de Boer, R. A. Galectin-3 in heart failure: An update of the last 3 years. Heart Fail. Clin. 14(1), 75\u201392. https:\/\/doi.org\/10.1016\/j.hfc.2017.08.009 (2018).","journal-title":"Heart Fail. Clin."},{"key":"12222_CR12","doi-asserted-by":"publisher","DOI":"10.4070\/kcj.2024.0093","author":"H Zhou","year":"2024","unstructured":"Zhou, H. et al. YAK577 attenuates cardiac remodeling and fibrosis in isoproterenol-infused heart failure mice by downregulating MMP12. Korean Circ. J. https:\/\/doi.org\/10.4070\/kcj.2024.0093 (2024).","journal-title":"Korean Circ. J."},{"key":"12222_CR13","doi-asserted-by":"publisher","first-page":"783707","DOI":"10.3389\/fcvm.2022.783707","volume":"9","author":"Z Cheng","year":"2022","unstructured":"Cheng, Z. et al. Prognostic value of serum galectin-3 in chronic heart failure: A meta-analysis. Front. Cardiovasc. Med. 9, 783707. https:\/\/doi.org\/10.3389\/fcvm.2022.783707 (2022).","journal-title":"Front. Cardiovasc. Med."},{"key":"12222_CR14","doi-asserted-by":"publisher","first-page":"797137","DOI":"10.3389\/fcvm.2022.797137","volume":"9","author":"Y Zha","year":"2022","unstructured":"Zha, Y. et al. ADAMTS8 promotes cardiac fibrosis partly through activating EGFR dependent pathway. Front. Cardiovasc. Med. 9, 797137. https:\/\/doi.org\/10.3389\/fcvm.2022.797137 (2022).","journal-title":"Front. Cardiovasc. Med."},{"issue":"12","key":"12222_CR15","doi-asserted-by":"publisher","first-page":"770","DOI":"10.1038\/s41581-024-00905-2","volume":"20","author":"SJ Allison","year":"2024","unstructured":"Allison, S. J. ECM remodelling by ADAMTS12 in fibrosis. Nat. Rev. Nephrol. 20(12), 770. https:\/\/doi.org\/10.1038\/s41581-024-00905-2 (2024).","journal-title":"Nat. Rev. Nephrol."},{"key":"12222_CR16","doi-asserted-by":"publisher","DOI":"10.1172\/JCI170246","author":"K Hoeft","year":"2024","unstructured":"Hoeft, K. et al. ADAMTS12 promotes fibrosis by restructuring extracellular matrix to enable activation of injury-responsive fibroblasts. J. Clin. Invest. https:\/\/doi.org\/10.1172\/JCI170246 (2024).","journal-title":"J. Clin. Invest."},{"issue":"6","key":"12222_CR17","doi-asserted-by":"publisher","first-page":"629","DOI":"10.1161\/CIRCRESAHA.111.243410","volume":"109","author":"JE Lopez","year":"2011","unstructured":"Lopez, J. E. et al. beta-myosin heavy chain is induced by pressure overload in a minor subpopulation of smaller mouse cardiac myocytes. Circ. Res. 109(6), 629\u2013638. https:\/\/doi.org\/10.1161\/CIRCRESAHA.111.243410 (2011).","journal-title":"Circ. Res."},{"key":"12222_CR18","doi-asserted-by":"publisher","DOI":"10.3390\/biom10091277","author":"A Hara","year":"2020","unstructured":"Hara, A. et al. Galectin-3: A potential prognostic and diagnostic marker for heart disease and detection of early stage pathology. Biomolecules https:\/\/doi.org\/10.3390\/biom10091277 (2020).","journal-title":"Biomolecules"},{"issue":"2","key":"12222_CR19","doi-asserted-by":"publisher","first-page":"149","DOI":"10.1136\/hrt.2003.018325","volume":"92","author":"GA Wright","year":"2006","unstructured":"Wright, G. A. & Struthers, A. D. Natriuretic peptides as a prognostic marker and therapeutic target in heart failure. Heart 92(2), 149\u2013151. https:\/\/doi.org\/10.1136\/hrt.2003.018325 (2006).","journal-title":"Heart"},{"issue":"10","key":"12222_CR20","doi-asserted-by":"publisher","first-page":"1323","DOI":"10.1007\/s00109-023-02370-z","volume":"101","author":"D Freiholtz","year":"2023","unstructured":"Freiholtz, D. et al. SPP1\/osteopontin: A driver of fibrosis and inflammation in degenerative ascending aortic aneurysm?. J. Mol. Med. (Berl.) 101(10), 1323\u20131333. https:\/\/doi.org\/10.1007\/s00109-023-02370-z (2023).","journal-title":"J. Mol. Med. (Berl.)"},{"issue":"5","key":"12222_CR21","doi-asserted-by":"publisher","first-page":"959","DOI":"10.1007\/s12265-022-10239-8","volume":"15","author":"M Zhou","year":"2022","unstructured":"Zhou, M. et al. Fibroblast-secreted phosphoprotein 1 mediates extracellular matrix deposition and inhibits smooth muscle cell contractility in Marfan syndrome aortic aneurysm. J. Cardiovasc. Transl. Res. 15(5), 959\u2013970. https:\/\/doi.org\/10.1007\/s12265-022-10239-8 (2022).","journal-title":"J. Cardiovasc. Transl. Res."},{"issue":"1","key":"12222_CR22","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1016\/s1357-2725(00)00061-3","volume":"33","author":"BL Tang","year":"2001","unstructured":"Tang, B. L. ADAMTS: A novel family of extracellular matrix proteases. Int. J. Biochem. Cell Biol. 33(1), 33\u201344. https:\/\/doi.org\/10.1016\/s1357-2725(00)00061-3 (2001).","journal-title":"Int. J. Biochem. Cell Biol."},{"issue":"3","key":"12222_CR23","doi-asserted-by":"publisher","first-page":"257","DOI":"10.1016\/j.toxlet.2014.02.016","volume":"226","author":"Y Li","year":"2014","unstructured":"Li, Y. et al. Chlorogenic acid prevents isoproterenol-induced hypertrophy in neonatal rat myocytes. Toxicol. Lett. 226(3), 257\u2013263. https:\/\/doi.org\/10.1016\/j.toxlet.2014.02.016 (2014).","journal-title":"Toxicol. Lett."},{"issue":"8","key":"12222_CR24","doi-asserted-by":"publisher","first-page":"519","DOI":"10.1016\/j.tips.2023.06.001","volume":"44","author":"S Bouffette","year":"2023","unstructured":"Bouffette, S., Botez, I. & De Ceuninck, F. Targeting galectin-3 in inflammatory and fibrotic diseases. Trends Pharmacol. Sci. 44(8), 519\u2013531. https:\/\/doi.org\/10.1016\/j.tips.2023.06.001 (2023).","journal-title":"Trends Pharmacol. Sci."},{"issue":"1","key":"12222_CR25","doi-asserted-by":"publisher","first-page":"107","DOI":"10.1161\/CIRCHEARTFAILURE.112.971168","volume":"6","author":"L Yu","year":"2013","unstructured":"Yu, L. et al. Genetic and pharmacological inhibition of galectin-3 prevents cardiac remodeling by interfering with myocardial fibrogenesis. Circ. Heart Fail. 6(1), 107\u2013117. https:\/\/doi.org\/10.1161\/CIRCHEARTFAILURE.112.971168 (2013).","journal-title":"Circ. Heart Fail."},{"key":"12222_CR26","doi-asserted-by":"publisher","DOI":"10.3390\/biomedicines10030585","author":"SM Ou","year":"2022","unstructured":"Ou, S. M. et al. Urinary galectin-3 as a novel biomarker for the prediction of renal fibrosis and kidney disease progression. Biomedicines https:\/\/doi.org\/10.3390\/biomedicines10030585 (2022).","journal-title":"Biomedicines"},{"key":"12222_CR27","doi-asserted-by":"publisher","first-page":"748225","DOI":"10.3389\/fmed.2021.748225","volume":"8","author":"SM Ou","year":"2021","unstructured":"Ou, S. M. et al. Identification of galectin-3 as potential biomarkers for renal fibrosis by RNA-sequencing and clinicopathologic findings of kidney biopsy. Front. Med. (Lausanne) 8, 748225. https:\/\/doi.org\/10.3389\/fmed.2021.748225 (2021).","journal-title":"Front. Med. (Lausanne)"},{"issue":"1","key":"12222_CR28","doi-asserted-by":"publisher","first-page":"57","DOI":"10.2332\/allergolint.O-06-449","volume":"56","author":"Y Nishi","year":"2007","unstructured":"Nishi, Y. et al. Role of galectin-3 in human pulmonary fibrosis. Allergol. Int. 56(1), 57\u201365. https:\/\/doi.org\/10.2332\/allergolint.O-06-449 (2007).","journal-title":"Allergol. Int."},{"issue":"3","key":"12222_CR29","doi-asserted-by":"publisher","first-page":"186","DOI":"10.1039\/d1mo00519g","volume":"18","author":"U Chalise","year":"2022","unstructured":"Chalise, U. et al. Macrophages secrete murinoglobulin-1 and galectin-3 to regulate neutrophil degranulation after myocardial infarction. Mol. Omics. 18(3), 186\u2013195. https:\/\/doi.org\/10.1039\/d1mo00519g (2022).","journal-title":"Mol. Omics."},{"issue":"1","key":"12222_CR30","doi-asserted-by":"publisher","first-page":"90","DOI":"10.1538\/expanim.21-0064","volume":"71","author":"L Yao","year":"2022","unstructured":"Yao, L., Shao, W., Chen, Y., Wang, S. & Huang, D. Suppression of ADAM8 attenuates angiotensin II-induced cardiac fibrosis and endothelial-mesenchymal transition via inhibiting TGF-beta1\/Smad2\/Smad3 pathways. Exp. Anim. 71(1), 90\u201399. https:\/\/doi.org\/10.1538\/expanim.21-0064 (2022).","journal-title":"Exp. Anim."},{"issue":"10","key":"12222_CR31","doi-asserted-by":"publisher","first-page":"884","DOI":"10.1161\/CIRCRESAHA.119.315398","volume":"125","author":"J Omura","year":"2019","unstructured":"Omura, J. et al. ADAMTS8 promotes the development of pulmonary arterial hypertension and right ventricular failure: A possible novel therapeutic target. Circ. Res. 125(10), 884\u2013906. https:\/\/doi.org\/10.1161\/CIRCRESAHA.119.315398 (2019).","journal-title":"Circ. Res."},{"issue":"1","key":"12222_CR32","doi-asserted-by":"publisher","first-page":"362","DOI":"10.1186\/s12931-024-02989-7","volume":"25","author":"B Yue","year":"2024","unstructured":"Yue, B. et al. SPP1 induces idiopathic pulmonary fibrosis and NSCLC progression via the PI3K\/Akt\/mTOR pathway. Respir. Res. 25(1), 362. https:\/\/doi.org\/10.1186\/s12931-024-02989-7 (2024).","journal-title":"Respir. Res."},{"issue":"4","key":"12222_CR33","doi-asserted-by":"publisher","first-page":"H733","DOI":"10.1152\/ajpheart.00339.2017","volume":"314","author":"ML Lindsey","year":"2018","unstructured":"Lindsey, M. L., Kassiri, Z., Virag, J. A. I., de Castro Bras, L. E. & Scherrer-Crosbie, M. Guidelines for measuring cardiac physiology in mice. Am. J. Physiol. Heart Circ. Physiol. 314(4), H733\u2013H752. https:\/\/doi.org\/10.1152\/ajpheart.00339.2017 (2018).","journal-title":"Am. J. Physiol. Heart Circ. Physiol."},{"key":"12222_CR34","doi-asserted-by":"publisher","first-page":"34790","DOI":"10.1038\/srep34790","volume":"6","author":"Y Ryu","year":"2016","unstructured":"Ryu, Y. et al. Gallic acid prevents isoproterenol-induced cardiac hypertrophy and fibrosis through regulation of JNK2 signaling and Smad3 binding activity. Sci. Rep. 6, 34790. https:\/\/doi.org\/10.1038\/srep34790 (2016).","journal-title":"Sci. Rep."},{"key":"12222_CR35","doi-asserted-by":"publisher","first-page":"677757","DOI":"10.3389\/fphar.2021.677757","volume":"12","author":"T Zhao","year":"2021","unstructured":"Zhao, T. et al. Selective HDAC8 inhibition attenuates isoproterenol-induced cardiac hypertrophy and fibrosis via p38 MAPK pathway. Front. Pharmacol. 12, 677757. https:\/\/doi.org\/10.3389\/fphar.2021.677757 (2021).","journal-title":"Front. Pharmacol."}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-12222-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-12222-0","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-12222-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,7,24]],"date-time":"2025-07-24T10:14:30Z","timestamp":1753352070000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-12222-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,7,24]]},"references-count":35,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["12222"],"URL":"https:\/\/doi.org\/10.1038\/s41598-025-12222-0","relation":{},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,7,24]]},"assertion":[{"value":"12 March 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 July 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 July 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"26925"}}